Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

• Status: Recruiting
• Trial end date: 2023-06-02
• Target enrollment: 0
• Participant gender: All

Summary

This is a Prospective, open, single arm study to evaluate the efficacy and safety of the almonertinib combined with concurrent chemoradiotherapy in unresectable stage III NSCLC with EGFR mutation

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yuan Chen

Criteria

Inclusion Criteria:

1. Age ≥18, male or female.

2. Patients must provide written informed consent to participate in the study.

3. Patients must have biopsy proven unresectable stage III NSCLC (AJCC 8th).

4. Patients must has sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R).

5. Patients receiving almonertinib for 3 months and achieved stable disease, partial response or completely response.

6. ECOG score 0-1

7. Demonstrate adequate organ function Patients evaluated as Cr, PR and SD were given concurrent chemoradiotherapy 3 months after targeted therapy

Exclusion Criteria:

1. Patients progress in 3 months after almonertinib treatment

2. Patient can't tolerate radiotherapy or targeted therapy

3. Pregnant or nursing women